GlucoTrack (NASDAQ:GCTK – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Insider & Institutional Ownership
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 8.4% of GlucoTrack shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
GlucoTrack has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GlucoTrack | N/A | N/A | -$19.39 million | ($18.04) | -0.02 |
| NeurAxis | $4.28 million | 20.66 | -$14.63 million | ($0.81) | -8.75 |
NeurAxis has higher revenue and earnings than GlucoTrack. NeurAxis is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for GlucoTrack and NeurAxis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GlucoTrack | 1 | 0 | 0 | 0 | 1.00 |
| NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis has a consensus price target of $13.00, suggesting a potential upside of 83.36%. Given NeurAxis’ stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than GlucoTrack.
Profitability
This table compares GlucoTrack and NeurAxis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GlucoTrack | N/A | -581.98% | -220.10% |
| NeurAxis | -492.76% | N/A | -641.25% |
Summary
NeurAxis beats GlucoTrack on 10 of the 13 factors compared between the two stocks.
About GlucoTrack
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
